Makhlouf Eman A, AlamElDeen Youmna K, El-Shiekh Riham A, Okba Mona M
Clinical Pharmacy PharmD Undergraduate Program, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Department of Pharmacognosy, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Nat Prod Res. 2024 Dec 13:1-16. doi: 10.1080/14786419.2024.2439009.
commonly known as Ashwagandha, is a prominent herb in Ayurvedic medicine, recognised for its diverse pharmacological properties, particularly its potential anti-diabetic effects. With the global incidence of diabetes mellitus (DM) surpassing 366 million, interest in herbal remedies like Ashwagandha has surged. Active compounds known as withanolides have demonstrated efficacy in modulating glucose homeostasis and enhancing insulin sensitivity. Systematic reviews indicate that Ashwagandha effectively restores altered blood glucose and glycosylated haemoglobin (HbA1c) levels without significant safety concerns. Animal studies reveal hypoglycaemic effects from both root and leaf extracts, improving metabolic parameters. Although clinical evidence remains limited, existing trials suggest that Ashwagandha may enhance insulin sensitivity and overall metabolic profiles in diabetic patients. This review underscores the potential of Ashwagandha as a complementary approach in DM management, warranting further research to confirm its therapeutic benefits and elucidate underlying mechanisms.
通常被称为印度人参,是阿育吠陀医学中的一种重要草药,因其多样的药理特性而闻名,尤其是其潜在的抗糖尿病作用。随着全球糖尿病(DM)发病率超过3.66亿,对印度人参等草药疗法的兴趣激增。被称为睡茄内酯的活性化合物已证明在调节葡萄糖稳态和增强胰岛素敏感性方面具有功效。系统评价表明,印度人参能有效恢复改变的血糖和糖化血红蛋白(HbA1c)水平,且无重大安全问题。动物研究揭示了根和叶提取物的降血糖作用,改善了代谢参数。尽管临床证据仍然有限,但现有试验表明,印度人参可能增强糖尿病患者的胰岛素敏感性和整体代谢状况。本综述强调了印度人参作为糖尿病管理补充方法的潜力,需要进一步研究以证实其治疗益处并阐明潜在机制。